Available online at http://www.nrjp.co.in

Journal of Management Science, Operations & Strategies, (E- ISSN 2456-9305) Vol. 4, Issue, 01. 81-94p, Jan to April 2020

National Research & Journal Publication

Review Article

VACCINE: A Tabloid History and Futuristic Approach Towards Immunization

[1]Amit Kumar Agarwal, [2]Tanya Jain, [3]Sandhya Agarwal and [4]Anshul Agarwal

[1]Department of chemistry, Agra College, Agra

[2, 3]Department of Biotechnology, Agra College, Agra

[4]Department of Applied science(Chemistry), FET, Agra College, Agra

Abstract

Vaccination is a crucial problem since 1800s for public health. Our ancient process of vaccination was more natural and cost effective. But current vaccination process is more time taking and may contain serious health effect also. It is clear that there are major challenges ahead to develop new vaccines for difficult-to-target pathogens, for which we deep need for more natural and less time taking vaccination system. Our Review reflects a Historical to present overview of vaccination system.

KEYWORDS: *- Vaccine concept, efficacy, side effects, morphology of microorganisms, vaccine duration.*

INTRODUCTION

One of the most important medical achievements of humankind is the prevention of diseases by vaccination. The use of vaccines currently prevents more than 3 million deaths per year. The average human life span has increased by 30 years during the 20th century. Same as in the US, the average life span has also shown an increment by more than 30 years since 1900, a significant portion attributed directly to vaccination. Vaccination for the first time was implemented on a wide scale more than 200 years ago with the introduction of the smallpox vaccine**.** After the smallpox vaccine, many more vaccines have produced by different companies. There is a great need today for improved understanding of the immunological basis for vaccination to develop vaccines for hard-to-target pathogens (such as Mycobacterium tuberculosis, the bacterium that causes tuberculosis (TB) and antigenic variable pathogens (such as HIV), to control outbreaks that threaten global health security (such as COVID-19 or Ebola) and to work out how to revive immune responses in the ageing immune system to protect the growing population of older adults from infectious diseases. Many new and improved vaccines are needed to decrease the rate of substantial morbidity and mortality caused by infectious diseases to put an end to this situation, certain suboptimal vaccines have to replace with better versions, and new vaccines are being introduced at a higher

frequency than ever before. It recognized that no antibody is completely protected or 100% effective. These advanced and updated immunizations have shown up in changes in the manner in which antibodies are created. This audit will cover an outline of the fundamental kinds of antibodies accessible today and their assembling. It would likewise incorporate how new advances have reformed how antibodies will make in the future. We have additionally given a few viewpoints on current and future difficulties for shielding the total populace from essential microbes and arising irresistible dangers.

WHAT IS VACCINE?

A *Vaccine* is a biological substance given to an individual to acquire active immunity against infection or disease. Vaccines are considered to be the lifeline of the human race. The vaccine works as a teacher who teaches our immunity system how to defend against infection or disease by creating an immune response. We can also say that vaccine is a biological product that can safely induce an immune response that confers protection against infection or disease on subsequent exposure to a pathogen. The antibody that achieves this effect should contain antigens from the microbe or be made artificially to address the microorganism's components. Vaccines are among the most effective tools available for preventing infectious diseases and their complications and sequelae. High immunization coverage has resulted in drastic declines in vaccine-preventable diseases, particularly in many high- and middle-income countries.

The words vaccine and vaccination are obtained from *Variolaevaccinae* (smallpox of the cow). This term was devised by Edward Jenner, who developed both the concept of vaccines and created the first vaccine to denote cowpox. He used the phrase in 1798 for the extended title of his Inquiry into the *Variolaevaccinae***.** Vaccination in India started in May 1802. A three-year-old child from Bombay, Anna Dusthall, became the first Indian to receive the smallpox vaccine in June 1802. Afterward, the vaccine was sent to Madras, Pune, Hyderabad, and Surat.

HISTORY OF VACCINE

The history of vaccines is hundreds of years old. In China, snake venom was used by Buddhist Monks to acquire immunity against snake bites. They also practiced variolation. Inoculation with variolous matter is known as variolation. It was the most widespread preventive against the disease. An example of variolation can be seen in the development of the smallpox vaccine developed by Edward Jenner. Smallpox Epidemics mopped across all over Europe in the seventeenth - eighteenth centuries, accounting for 29% of the death of children in London. While coming towards 1796, Edward Jenner successfully created immunity to smallpox using cowpox material, quickly the practice widespread. Jenner’s demonstration, material from cowpox sores taken from a milkmaid’s hands, Sarah Nelms was put into the skin of an 8-year-old kid James Phipps. This test with smallpox disease gives early proof that immunization could work. Jenner’s contribution to medicine was not the method of inoculation but his unexpected observation that milkmaids who had mild cowpox infections didn’t contract smallpox and the serendipitous opinion

that material from cowpox lesions might give immunity against smallpox disease.

Moreover, Jenner intelligently predicted that the eradication of smallpox could be possible by vaccination. Finally, in 1980, the world is declared free from naturally occurring smallpox by the World Health Assembly. The World Health Organization launched the augmented Programme on immunization in 1974. World Health Organization set up a goal in 1977 to give every child in the world vaccines of diphtheria, pertussis, tetanus, poliomyelitis, measles, and vaccine of T.B by 1990. But unfortunately, for some reason, that objective has still not been reached; however, the global coverage of 3 doses of diphtheria-tetanus-pertussis vaccine has exceeded 85%. There are more than 19 million children who have not yet received the required vaccinations. Safe and effective prophylactic vaccines are urgently needed to fight the pandemic, devastating medical, economic, and social consequences. Vaccines have transformed public health since national programs for immunization first became properly established and coordinated in the 1960s.

We need more effective vaccines against viruses as we all know earlier versions of vaccines were based on living but harmless, weakened, and killed disease-causing agents. These strategies are still used, as are approaches that use isolated proteins or carbohydrates as antigens.

NEED OF VACCINE

For many centuries, Humankind was exterminated by smallpox. In modernity, we do not have to worry about it, and all the credit for it goes to the remarkable work of Edward Jenner and later developments in the field of vaccinology. After the World Trade Centre attack on 11 September 2001, the threat of biological warfare and bioterrorism has re-emerged and is likely to cause significant harm to mankind11. After the emplacement of the Global EPI programme (1974), new vaccines have been introduced in the market, including Haemophilus influenzae serotype b (Hib), hepatitis B, pneumococcal, and meningococcal polysaccharide/protein conjugate, rotavirus, and human papillomavirus (HPV) vaccines. Despite their proven efficiency and a high burden from many of the diseases they could prevent, the uptake of these vaccines in the developing world has been slow. The development of the next generation of vaccines is increasingly challenging as many of the organisms they target have complex structures and life cycles. The new vaccines development against other important infectious targets such as dengue or novel coronaviruses should be easier using established technologies. Still, the modest efficacy of a recently tested dengue vaccine emphasizes that challenges remain even in developing more conventional vaccines. Effective vaccines will probably be developing against significant infections such as HIV, TB, and malaria. Still, the prediction of time is difficult that how long this will take. Ultimately, these infections will cease to be a significant public health priority even if infections cannot eradicate them. Ensuring the maximum benefit that vaccination can provide against infectious diseases will be achieved. Imagine there is global, high-level surveillance to detect new, potentially dangerous infections. Moreover, identify the emergence of strains resistant to the vaccines in routine use as quickly as possible. In that case, countermeasures can be put into place. As

the incidence of infectious diseases declines and living standards improve across the developing world. Many developing countries are entering a transition phase. We have a residual challenge from infectious diseases, such as HIV and tuberculosis. At the same time, we are experiencing significant difficulties emerging from non-infectious diseases such as diabetes, cardiovascular disease, and cancer. Both DNA and RNA viruses are capable of causing cancer in humans. Epstein-Barr virus, human papillomavirus, hepatitis B virus, and human herpes virus-8 are four DNA viruses capable of causing the development of human cancers. The Human T lymphocytic virus type 1 and hepatitis C virus are the two RNA viruses that contribute to human cancers**.** Identifying specific tumour antigens (tumour-associated antigens) that are present only in cancer cells—such as those found in leukaemia, breast cancer, melanoma, prostate cancer, and colon cancer—provides immune targets for which immunogenic vaccines may conceivably be designed. Diseases related to pathological immune activation, such as autoimmune diseases and allergies, might be treatable or preventable with vaccines. Many efforts are established to develop vaccines against rheumatoid arthritis, multiple sclerosis, myasthenia gravis, food allergies, and especially diabetes type one because of its associated substantial morbidity and mortality. Interest has increased in biological weapons of mass destruction as terrorists look for methods to inflict harm on the most significant number of people, with the lowest possible cost and technology needs, while creating mass panic. There is a prominent need today for an improved understanding of the immunological basis for vaccination to acquire vaccines for hard-to-target pathogens (such as Mycobacterium tuberculosis, the bacterium that causes tuberculosis (TB), and antigenically mutable pathogens (such as HIV). To manage outbreaks that threaten global health security (such as COVID-19 or Ebola) and work out how to improve immune responses in the aging immune system to protect more aged grown-ups expanding population from contagious diseases. One of the most critical needs of an effective vaccine is the use of biological weapons in warfare. Because biological weapons can infect and kill large numbers of the population and the risk of person-to-person transmission, vaccines are likely to be the only practical means of protection. Second-generation vaccines against anthrax, smallpox, and plague are being developed, and vaccines against other agents of bioterrorism such as the haemorrhagic fever viruses and others are also in development. Major obstacles in the production of such vaccines for public use include the need for a financially viable market, the difficulty of conducting human efficacy trials, the intangible risk: benefit ratio at the public health level, and the government's reluctance to face the reality of bioterrorism.

LONG TERM SOLUTION - HERD IMMUNITY

Herd immunity results when a virus cannot spread because it keeps encountering people who are immune against infection. When a fair proportion of the population is no longer susceptible, any new outbreak peters out. Herd immunity is a crucial concept for epidemic control. It states that only a proportion of a population needs to be immune (through overcoming natural

infection or through vaccination) to an infectious agent to stop generating large outbreaks. Measles, mumps, polio, and chickenpox are some infectious diseases that were once pretty well-known. Still, today they are rare in the U.S. because vaccines are supported to establish herd immunity. Some other Viruses like the flu mutate over time, so antibodies from the previous infection do not protect for a long course. For the flu virus, this is less than a year. Suppose SARS-CoV-2, the virus that causes COVID-19, is like other corona viruses that currently infect humans. In that case, we can expect that people who get infected will be immune for months to years, but probably not their entire lives. When most of society is immune to an infectious disease, this provides indirect protection or herd immunity, also called herd protection, to those who are not resistant to the disease. For example, suppose 80% of a population is immune to a virus. In that case, four out of every five people who encounter someone with the disease will not get sick (and will not spread the disease further). In this way, the spread of infectious diseases is under control. Depending on how contagious infection is, usually, 50% to 90% of a population needs immunity to achieve herd immunity.

DRAWBACKS OF VACCINE

Along with various economic benefits of vaccines, there are also some drawbacks of vaccines that drawbacks cannot ignore at all. This era of biotechnology has administered several changes in the companies working for the manufacturing of vaccines. However, challenges in this area are increasing day by day. The most crucial problem that arises in the manufacturing and transport of vaccines is maintaining the cold chain. The global distribution becomes difficult because of cold chain reaction. Another critical parameter to be considered is the maintenance of its thermo stability. Vaccine distribution has become the most significant obstacle because of refrigerated transport of solution-based vaccines. Even WHO has reported that around 2.8 million vaccines were lost due to cold chain failure. Cold chain maintenance has been the major issue faced by underdeveloped and developing countries with tropical climates.

COVID-19: RISING THREAT TO MANKIND

DIFFERENT VARIANTS OF CORONA VIRUS

VOC: Variant of Concern
VOI: Variant of Interest

NAME GIVEN BY WHO	EARLIEST SAMPLES WITH DOCUMENTATION	DATE OF DESIGNATION
Alpha	United Kingdom, Sep-2020	18-Dec-2020
Beta	South Africa, May-2020	18-Dec-2020
Delta	India, Oct-2020	VOI: 4-Apr-2021 VOC: 11-May-2021

Delta plus	India,	VOC: April-2021
Eta	Multiple countries, Dec-2020	VOI: 17-Mar-2021
Gamma	Brazil, Nov-2020	11-Jan-2021
Iota	United States of America, Nov-2020	VOI: 24-Mar-2021
Kappa	India, Oct-2020	VOI: 4-Apr-2021
Lambda	Peru, Dec-2020	VOI: 14-Jun-2021

IMMUNITY

For those who gained immunity through the COVID infection, one dose typically boosts their numbers of antibodies to levels equal to, or often more significant than, those found in individuals who have not been infected and have received double doses. Guiliana Magri, an immunologist at hospital del Mar Research Institute in Barcelona, Spain, said that probably one dose of vaccine is sufficient if someone was infected with the COVID-19 virus.

THREAT TO MANKIND

Viral Diseases would continue to emerge and represent a severe health issue, according to the World Health Organization (WHO). Several viral epidemics that happened in the preceding twenty years, such as the severe acute respiratory syndrome coronavirus (SARS-CoV) and H1N1 influenza in 2009, have caused panic worldwide. On 11 February 2020, the WHO Director-General, Dr. Tedros Adhanom Ghebreyesus, announced that the disease caused by this new CoV is "COVID-19," which is an acronym for “coronavirus disease 2019’’

The WHO identified the outbreak's causative agent as the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), produced the disease named coronavirus disease-2019 (COVID-19). The virus is similarly related (96.3%) to bat coronavirus RaTG13, discovered by phylogenetic analysis. Even in asymptomatic carriers, Human-to-human transmission has been confirmed. At least 200 countries trapped in this corona outbreak. More than 21 core confirmed cases and 45 lakh deaths were recorded, with massive global increases in the number of cases daily. Therefore, the WHO has declared COVID-19 a pandemic. The COVID-19 pandemic can be considered a global unifier, with countries worldwide all challenged to contain the spread of SARS-CoV-2. Coronaviruses are enveloped, icosahedral symmetric particles and single-strand RNA viruses that can infect many hosts, including avian, wild, domestic mammalian species, and humans. Coronaviruses are known for their rapidly mutating ability, altering tissue tropism,

overcoming species inhibition, and adapting to various epidemiological conditions. The illness has side effects of fever, dry hack, and chest torment with pneumonia in extreme cases. First, the world's general wellbeing specialists attempted to destroy *China's sickness* through quarantine but are now transitioning to prevention strategies worldwide to delay its spread. Coronavirus disease 2019 (Covid-19) has affected tens of millions of people globally since it was declared a pandemic by the World Health Organization on 11 March 2020.

S. No	Name	Vaccine Type	Primary Developers	Efficacy	Adverse effect	Dosage	Storage Temp.
1)	Comirnaty (BNT162b2) (Multinational)	mRNA-based vaccine	Pfizer, BioNTech; Fosun Pharma	16 to 55 years: 95.6 (89.4, 98.6) ≥55 years: 93.7 (80.6, 98.8) ≥65 years: 94.7 (66.7, 99.9) Overall: 95.0 (90.0, 97.9)	The adverse effect profile of the Pfizer-BioNTech COVID-19 vaccine is similar to that of other adult vaccines. During clinical trials, the side effects deemed very common [a] are (in order of frequency): pain and swelling at the injection site, tiredness, headache, muscle aches, chills, joint pain, and fever.Fever is more common after the second dose.	A two-dose regimen of BNT162b2 (30 μg per dose, given 21 days apart)	−80 & −60 °C (−112 and −76 °F)
2)	mRNA-1273 (US)	mRNA-based vaccine	Moderna, Barda, Niaid	Vaccine efficacy in participants aged ≥65 years was 86.4% compared with 95.6% in participants aged 18 to <65 years.	**Adverse Effects>10%** Injection site pain (86.9%), Fatigue (38.4%), Headache (35.3%), Myalgia (23.7%), Use of antipyretic/analgesic medication (23.3%), Axillary swelling/tenderness (11.6%) **Adverse Effects: 1-10%** Nausea/vomiting (9.4%), Chills (9.2%), Swelling(6.7%), Pain(3.2%), Erythema (3%), Headache(1.9%), Fatigue (1.1%). **Adverse Effects <1%** Fever (0.9%), Myalgia (0.6%), Swelling (0.5%), Arthralgia (0.4%), Axillary swelling/tenderness(0.3%), Erythema (0.3%), Chills(0.1%), Fatigue(<0.1%), Arthralgia(<0.1%), Nausea/vomiting(<0.1%), Fever(<0.1%)	ADULT: - injection, suspension 100mcg/0.5mL per dose Each multiple-dose vial contains 10 doses	Store frozen at -25ºC to -15ºC (-13ºF to 5ºF)
3)	CoronaVac (China)	Inactivated vaccine	Sinovac	On 24 December 2020, Turkey released Phase III results from an interim analysis of 29 cases which showed an efficacy rate of 91.25% based only on the data of 1,322 participants in a trial involving 7,371 volunteers. On 11 January, Indonesia released Phase III results from an interim analysis of 25 cases which showed an efficacy rate of 65.3% based on data of 1,600 participants in the trial.	The incidence rate of unsolicited adverse reactions was 36.83%, the symptoms were mainly runny nose (7.01%). sore throat (6.93%), nasal congestion (2.74%), abdominal pain (1.34%) and dizziness (0.66%	The 3 μg dose of CoronaVac is the suggested dose for efficacy assessment in future phase 3 trials.	2–8 °C (36–46 °F)

4)	COVID-19 Vaccine AstraZeneca (AZD1222) (UK)	Adenovirus vaccine	BARDA, OWS		Tenderness, swelling and/or redness at the injection site, headache, muscle ache, drowsiness, fever (temperature above 37.8°C).	more than 14 days after the second dose	2–8 °C (36–46 °F) for at least six months
5)	Sputnik V (Russia)	Non-replicating viral vector	Gamaleya Research Institute, Acellena Contract Drug Research and Development	Second interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose; vaccine efficacy is over 95% 42 days after the first dose.	Weakness, muscle pain for 24 hours and an occasional increase in body temperature.	The Sputnik V - the two-dose schedule vaccine has been administered to the people who are 18 years of age and above. The second dose should be taken after 21 days / 3 weeks gap of the first dose.	2–8 °C (36–46 °F)
6)	Covaxin (India)	Inactivated vaccine	Bharat Biotech, ICMR	This vaccine can be 78-95% effective after the second dose.	Injection site pain, swelling, redness, itching, stiffness in the upper arm, weakness in the injection arm, body ache, headache, fever, malaise, weakness, rashes, nausea, and vomiting. Vaccine can cause severe allergic reactions including difficulty in breathing, swelling on face and throat, a fast heartbeat, rash all over your body, dizziness and weakness.	2 doses (3 weeks apart)	2–8 °C
7)	Covishield	It is a recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 Spike (S) glycoprotein.	Bharat Biotech, ICMR	This vaccine can be 70%-90% in different trials	The SII has stated that “very common” side effects that may affect more than 1 in 10 people are tenderness, pain, warmth, redness, itching, swelling, or bruises where the injection is given, generally feeling unwell, fatigue, chills, or feeling feverish, headache, nausea, and joint pain or muscle ache.	2 doses (4 or 6 weeks apart)	Stable in refrigerator for at least 6 months

PROTEST AGAINST VACCINE

Pork-inferred gelatin has been generally utilized as a stabilizer to guarantee antibodies stay protected and powerful during stockpiling and transport18. Some people said that any vaccine containing pork was not permissible. The gelatin used in some Vaccines is derived from a pig which is not acceptable to some communities. According to communities’ law, a vaccine that contains pig gelatin cannot be used as a treatment for any disease.”19. This presents a dilemma for religious communities where the consumption of pork products is deemed religiously unclean.

CO-MORBIDITY

More seasoned grown-ups and individuals with severe hidden ailments like the heart,

lung infection or diabetes appear to be a more prominent risk of growing more genuine entanglements from COVID-19 disease. Co-morbidities increase the chances of infection. The older, weak populace, with persistent ailments, for example, diabetes and cardiovascular or lung infection are not just at a more prominent danger of creating severe disease but at the same time are at expanded risk of death on the off chance that they become sick. Individuals with fundamental uncontrolled ailments, for example, diabetes; hypertension; lung, liver, and kidney illness; disease patients on chemotherapy; smokers; relocate beneficiaries, and patients taking steroids persistent, are at an expanded danger of COVID-19 contamination. Patients with moderate to severe asthma are off guard since this infection influences their respiratory plots, prompting expanded asthmatic assaults, pneumonia, and intense respiratory trouble.

USE OF POLY ETHYLENE GLYCOL AND ITS NEGATITVITY

Both the immunizations created by Pfizer-BioNTech and Moderna contains Poly Ethylene Glycol as their main ingredient.[24] They have PEG as a part of the fatty envelope that surrounds the messenger RNA (the main ingredient in the vaccine); this is known as the Mapping process. As indicated by researchers, hypersensitivities to PEG are the most extraordinary of uncommon cases. This compound is likewise present in different items, including beauty care products, nourishments, and medications. A few antibodies likewise contain PEG-like mixtures. The stake has never been utilized in an affirmed antibody. However, it is found in numerous medicines that have often set off hypersensitivity—a conceivably hazardous response that can cause rashes, a diving pulse, windedness, and a quick heartbeat. A few allergists and immunologists accept few individuals recently presented to PEG may have undeniable degrees of antibodies against PEG, putting them in danger of an anaphylactic response to the immunization. The two vaccines contain mRNA enveloped by lipid nanoparticles (LNPs) that help convey it to human cells and go about as an adjuvant. This immunization fixing supports the immune reaction. The LNPs are "PEGylated"—synthetically appended to PEG atoms that cover the particles' outside and increment their dependability and life expectancy. Simply a month ago, Phillips and researchers at the FDA and different foundations distributed a paper showing patients who endured an anaphylactic response to PEGylated drugs had IgE antibodies to PEG, all things considered, proposing that they might be included, as opposed to IgG and IgM27.

The race to find an effective vaccine is becoming a more crucial concern every day. An American pharmaceutical company Pfizer has announced that they have successfully produced a COVID-19 vaccine, which is 90% effective. Still, there is a downside. It has to be put at a temperature of -70 degrees Celsius. It isn't easy to maintain -70°C even in large cities; imagine how we can keep this temperature in remote areas? There is another vaccine named Novavax; the most significant advantage of this vaccine is that the antibodies in this vaccine are six times more effective from a recovered patient of COVID-19. And there is another advantage; it has to be put at 2-8°C barley can be achieved easily. The Russian Sputnik V very famous COVID-19 vaccine; is the same as Novavax. It gets so much popularity because it is the world's first vaccine for covid1930.

OUR HYPOTHESIS AND FUTURE WORK

One of the most successful tools for disease prevention available nowadays is vaccines, resulting in the complete eradication of some diseases and others

successful control. But, new ways to use existing vaccines.

We can make existing vaccines even more effective by finding smarter ways to target specific at-risk groups in society. For example, giving a vaccine with a killed pathogen to a pregnant woman will boost antibody levels in the mother, allowing the extra antibodies to reach her unborn baby. Doing this protects her new born baby while the baby's immune system is still maturing, providing immunity to baby from birth. A mother is holding up her baby, When a pregnant woman is successfully immunising against disease, she can pass protective antibodies to her unborn child. Another way to use existing vaccines more effectively is by targeting them to the elderly. For instance, older adults in hospitals are more prone to several vaccine-preventable diseases such as Streptococcus pneumoniae, influenza virus and shingles-causing varicella.

There are loads of possibilities waiting to make vaccines even better. New ways of handling and transporting existing vaccines are in development, while researchers create new vaccines to target a more comprehensive range of diseases.

NEW TECHNOLOGIES FOR VACCINE DELIVERY

For a vaccine to effectively stimulate a protective immune response, it needs to get past one significant barrier: the skin, which is our body's first line of defence against disease. That is why so many vaccines need to injected under the skin into the muscle. A fear of needles can be a significant barrier for many people in getting a vaccination. Fortunately, new technologies are under development that will mean fewer injections (such as combining several vaccines into one-shot), or even using technology that uses no needles.

Some vaccines can already be delivered orally (polio vaccine) or via a nasal spray (influenza vaccines). Researchers are also working on innovative delivery methods such as needle-free skin patches and micro-needle injection technologies for a less painful vaccination experience. Someone using a nasal spray some vaccines can already deliver without the need for injections.

NEW VACCINES

Present research is focusing on completely new antibodies and improved renditions of existing immunizations. For example, vaccines against influenza currently need to be re-developed each year to keep up with the ever-changing virus involved. However, a universal influenza vaccine could be on the way as researchers find different ways to target the virus regardless of these changes. Most successful vaccines work by prompting our immune system to produce antibodies against a target disease. However, standard approaches do not work so well for some diseases, either because our immune system does not respond as it usually would, or because a pathogen finds other ways around our defences. HIV/AIDS and malaria are two examples of diseases which are notoriously difficult to vaccinate against thanks to rapidly-mutating pathogens that can also 'hide' from crucial parts of the immune system. Nevertheless, there is now a licensed vaccine for malaria that provides partial protection against the disease. Scientists also continue to make progress towards developing an experimental HIV vaccine for use in clinical trials. Immunisation still has so much more to offer global health in developed and developing countries around the world. Vaccines also have the potential to treat, in addition to preventing, both infectious and non-infectious diseases. Such 'therapeutic' vaccines target persistent infections (such as shingles and human papillomavirus-induced tumours) and non-infectious conditions, including

autoimmune disorders, allergies, and other cancers are not known to be infection-related. These vaccines may work by amplifying the body's anti-tumour immune response, or (in the case of autoimmune or allergic disorders) by switching off the unwanted immune responses responsible for these conditions.

USE OF VLPS IN VACCINE DEVELOPMENT

During the previous few years, the utilization of VLPs for the assembling of immunizations is becoming more popular. For example, the H1N1 influenza vaccine developed jointly by Novovax and Cadila Pharmaceuticals uses VLPs. The advantages of a VLP-based vaccine platform are that it uses a recombinant-vaccine technology. There are no safety concerns and the process is easily scalable to large quantities and more economical in terms of facility, materials, labour, and utility costs. Other VLP-derived vaccines include Merck's Gardasil, which protects against human papillomavirus types 6, 11, 16, and 18. If we would work at molecular level, we will be able to manufacture more fine vaccines.

Notwithstanding the novel antibody stages referenced above, there are continuous endeavours to create improved antigen conveyance strategies. For example, these, and different strategies, self-gathering protein Nano particles, can ideally upgrade and slant the safe reaction to microbes against which conventional immunization approaches have demonstrated to be fruitless. In our future project of vaccine, we would introduce a new way of manufacturing vaccine by making VLP with the help of nanotechnology.

During the previous few years, the utilization of VLPs for the assembling of immunizations is becoming more popular. For example, the H1N1 influenza vaccine developed jointly by Novovax and Cadila Pharmaceuticals uses VLPs. The advantages of a VLP-based vaccine platform are that it uses a recombinant-vaccine technology. There are no safety concerns, and the process is easily scalable to large quantities and more economical in terms of facility, materials, labor, and utility costs. Other VLP-derived vaccines include Merck's Gardasil, which protects against human papillomavirus types 6, 11, 16, and 18. If we would work at the molecular level, we will be able to manufacture more good vaccines.

Notwithstanding the novel antibody stages referenced above, there are continuous endeavor’s to create improved antigen conveyance strategies. For example, these, and different strategies, self-gathering protein nanoparticles, can ideally upgrade and slant the safe reaction to microbes against which conventional immunization approaches have demonstrated to be fruitless. In our future vaccine project, we would introduce a new way of manufacturing vaccines by making VLP with the help of nanotechnology.

CONCLUSION

Vaccination protects low immunity populations from deadly diseases. A partial understanding of vaccination and immune mechanisms hampered they architect of efficient vaccine against deadly disease such as hepatitis C, HIV, (to be added) now it is clear that change in host response is a key factor for vaccination mechanism. Nanotechnology and spectroscopic techniques will clear the complex immune mechanism involved in future. Despite of scientific challenges, social and political obstruction stands in the way of efficient vaccine manufacturing and vaccination access.

Improving refrigerating infrastructure (cold chain) will be essential to betterment this. (add point related to peg) coordinated collaboration between scientists and politicians will be imperative to move forward. The COVID-19 pandemic has

shown that, in the case of an emergency, we together (entire globe) can develop a vaccine in a shorter period.

ACKNOWLEDGEMENT

Thanks to Principal, Agra College, Agra, for providing a platform to work, HOD Biotechnology Department, Agra College, Agra and special Thanks to Mr. Himanshu Vashistha and Mr. Chanchal Tomar.

REFERENCES

1. Jeffrey B Ulmer, Ulrich Valley & RinoRappuoli (November 2006). Vaccine Manufacturing: Challenges and Solutions. Nature Biotechnology. Volume 24. Number 11. 1377-1378.

2. Cooper, M.R., Stewart, D.C., Kahl, F.R., Brown, W.M. & Cordell, A.R (2002). Medicine at the medical center then and now: one hundred years of progress. South. Med. J. 95, 1113–1121

3. Chen RT, Hibbs B (July 1998). Vaccine Safety: Current andFuture Challenges. Pediatric Annals; 27 (7): 445-455.

4. Andrew J. Pollard and Else M. Bijker (2021). A Guide to Vaccinology: From Basic Principles to New Developments. Nature Reviews. Immunology.

5. Omer SB, Salmon DA, Orenstein WA, DeHart MP, Halsey N (2009). Vaccine refusal, Mandatory Immunization and the Risks of Vaccine-preventable diseases. NEJM ; 360:1981–8

6. The history of vaccine https://www.historyofvaccines.org/timeline/all

7. The Immunization Advisory Centre. https://www.immune.org.nz/vaccines/vaccine-development/brief-history-vaccination

8. Monica Gandhi, M.D., M.P.H., and George W. Rutherford, M.D. Facial (2020) Masking for Covid-19 — Potential for "Variolation" as We Await a Vaccine. NEJM. PERSPECTIVE. e101(2)

9. Fernando P. Polack, M.D., Stephen J. Thomas, M.D., Nicholas Kitchin, M.D., Judith Absalon, M.D., Alejandra Gurtman, M.D., Stephen Lockhart, D.M., John L. Perez, M.D., Gonzalo Pérez Marc, M.D., Edson D. Moreira, M.D., Cristiano Zerbini, M.D., Ruth Bailey, B.Sc., Kena A. Swanson, Ph.D., SatrajitRoychoudhury, Ph.D., Kenneth Koury, Ph.D., Ping Li, Ph.D., Warren V. Kalina, Ph.D., David Cooper, Ph.D., Robert W. Frenck, Jr., M.D., Laura L. Hammitt, M.D., ÖzlemTüreci, M.D., Haylene Nell, M.D., Axel Schaefer, M.D., SerhatÜnal, M.D., Dina B. Tresnan, D.V.M., Ph.D., Susan Mather, M.D., Philip R. Dormitzer, M.D., Ph.D., UğurŞahin, M.D., Kathrin U. Jansen, Ph.D., and William C. Gruber, M.D., for the C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine; 2.

10. Amber Dance (2020). Covid-19 Vaccines Get Biotech Boost. Nature. 583:648-9

11. Stefan Riedel (2005 Jan). Edward Jenner and the History of Smallpox and Vaccination. Baylor University Medical Centre Proceedings. 18(1): 21–25.

12. Brian Greenwood (2014).The Contribution of Vaccination to Global Health: Past, Present and Future. Philosophical Transaction. The Royal Society. 369(1645)

13. Gregory A Poland, Dennis Murray, Ruben Bonilla-Guerrero (2002 Jun). Science, Medicine and the Future:

New Vaccine Development.BMJ. 1; 324(7349): 1315–1319.

14. Christie Aschwanden (2020). The False Promise of Herd Immunity. Nature. November. Vol 587. 26-28.

15. Arnaud Fontanet, Simon Cauchemez (2020). Covid-19 Herd Immunity: Where are we? Nature Reviews Immunology. Volume 20. 583–584.

16. Gypsyamber D'Souza, David Dowdy (April 2020). What is Herd Immunity and How Can we Achieve it with COVID-19? Johns Hopkins Bloomerg School of Public Health. Articles.

17. Marco Cascella; Michael Rajnik; Arturo Cuomo; Scott C. Dulebohn; Raffaela Di Napoli (2020 Jan). Features, Evaluation, and Treatment of Coronavirus. NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Article 52171.s1

18. https://economictimes.indiatimes. com/ news/international/world-news/ concern-among-muslims-over-halal-status-of-covid-19-vaccine/article show/79822037.cms?from=mdr

19. https://www.indiatvnews.com/news/ india/aaj-ki-baat-december-23-rajat-sharma-blog-post-opinion-673669

20. https://www.businesstoday.in/ coronavirus/covid-19-vaccine-halal-certification-a-concern-for-muslims/story/425472.html

21. CDC. Coronavirus (COVID-19): symptoms of coronavirus. Centers for Disease Control and Prevention. 2020. [Accessed April 18, 2020, https://www.cdc.gov/coronavirus/2019 -ncov/symptoms-testing/symptoms.html]

22. Adekunle Sanyaolu, Chuku Okorie, Aleksandra Marinkovic, Risha Patidar, Kokab Younis, Priyank Desai, ZaheedaHosein, Inderbir Padda, Jasmine Mangat and Mohsin Altaf (2020). Comorbidity and its Impact on Patients with COVID-19.

23. 1-8. doi:10.1007/s42399-020-00363-4.

23. BCCDC. COVID-19 vulnerable populations. British Columbia Centre for Disease Control. 2020. [Accessed April 18,2020, http://www.bccdc.ca/ health-info/diseases-conditions/covid-19/vulnerable-populations]

24. https://www.sciencemag.org/ news/2020/12/suspicions-grow-nanoparticles-pfizer-s-covid-19-vaccine-trigger-rare-allergic-reactions

25. https://www.thehindubusinessline. com/news/science/researchers-speculate-peg-compound-behind-allergic-reactions-to-covid-19-vaccine-report/article33430045.ece

26. https://www.sciencemag.org/news /2020/12/suspicions-grow-nanoparticles-pfizer-s-covid-19-vaccine-trigger-rare-allergic-reactions

27. https://www.jacionline.org/article /S0091-6749(16)30605-4/fulltextPre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer

28. https://www.pharmamanufacturing. com/industrynews/2020/novavax-coronavirus-vaccine-produces-antibodies-in-early-stage-trial/

29. https://www.genengnews.com/ news/the-cold-truth-about-covid-19-vaccines/

30. Jon Cohen. Russia's approval Covid-19 Vaccine is less than meets the press release. Science magazine. August

2011. [https://www.sciencemag.org/news/2020/08/russia-s-approval-covid-19-vaccine-less-meets-press-release]

31. Arindam Nandi , Anita Shet (2020). Why Vaccines Matter: Understanding the Broader Health, Economic, And Child Development Benefits of Routine Vaccination

32. Challenges and Trends in Vaccine Manufacturing. BioPharm International, BioPharm International-10-02-2011, Volume 2011 Supplement, Issue 7

33. Matthew D. Shin, Sourabh Shukla, Young Hun Chung, Veronique Beiss, Soo Khim Chan, Oscar A. Ortega-Rivera, David M. Wirth, Angela Chen, Markus Sack, Jonathan K. Pokorski& Nicole F (2020). Steinmetz COVID-19 Vaccine Development and A Potential Nanomaterial Path Forward. Nature Nanotechnology 15, 646–655

34. Kristensen, D. D., Lorenson, T., Bartholomew, K. &Villadiego, Shirley villadiego (2016). Can Thermostable Vaccines Help Address Cold-Chain Challenges? Results from Stakeholder Interviews In Six Low- And Middle-Income Countries. Vaccine 34, 899–904 .

35. https://www.sciencedirect.com/science/article/pii/S0264410X98002072?via%3Dihub

36. Chandrakant Lahariya (2014). A Brief History of Vaccines and Vaccination inIndia.Indian J Med Res. Apr; 139(4): 491–511.

37. John B Liao (2006). Viruses and Human Cancer. Yale Journal of Biology and Medicine. Dec; 79(3-4): 115–122.

38. Elie Dolgin. Is one vaccine dose enough if you've had COVID? What the science says 2021. [Accessed 25 June 2021 https://www.nature.com/articles/d41586-021-01609-4]